Overall, we have demonstrated that anti-PD-L1 antibody treatment can drive T cell immune responses and override the radiotherapy tolerance of BC cells by modulating the miR-21/PDCD4/PI3K/Akt/PD-L1 axis (Figure 6). This evidence concerns the gene PDCD4 and breast cancer.